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Total nucleated (TNCs) and CD34þ cells are considered major determinants of outcome after umbilical cord
blood (UCB) transplantation but the effect of other cell subtypes present in the graft is unknown. This single-
center cohort study included patients with hematological malignancies who received UCB transplantation
after a myeloablative conditioning regimen. UCB units were primarily selected according to cell content, both
TNCs and CD34þ cells, and also according to the degree of HLA matching. Counts of several cell subtypes of
the infused UCB unit, together with HLA disparities and other patient- and transplantation-related charac-
teristics, were analyzed by multivariable methodology for their association with myeloid and platelet
engraftment, graft-versus-host disease, nonrelapse mortality (NRM), disease-free survival (DFS), and overall
survival (OS). Two hundred patients (median age, 32 years) were included in the study. In multivariable
analyses, a greater number of CD8þ cells was signiﬁcantly associated with better results for myeloid (P ¼ .001)
and platelet (P ¼ .008) engraftment, NRM (P ¼ .02), DFS (P ¼ .007), and OS (P ¼ .01). CD34þ cell content was
predictive of myeloid engraftment (P < .001). This study suggests that the outcome after UCB transplantation
in adults with hematological malignancies could be better when UCB grafts had a greater CD8þ cell content.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Umbilical cord blood (UCB) transplantation (UCBT) is a
curative procedure for patients with hematological disorders
who require an allogeneic hematopoietic cell transplantation
but lack a suitable adult donor [1].
Cell dose and degree of HLA matching between the UCB
unit and the recipient are critical determinants of the
outcome after UCBT and used for guiding the selection of the
UCB unit [1-3]. The cell dose measurement universally
employed is the number of total nucleated cells (TNCs)
because it is reproducible, has shown prognostic impact
[4,5], and constitutes a good surrogate of CD34þ cell content
and the potency of the graft [3]. However, CD34þ cell dose
has only occasionally been associated with long-termedgments on page 1750.
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mains undeﬁned.
The aim of this study was to analyze the impact on
outcome of different cell populations of the UCB unit in a
large series of adult patients with hematological malig-
nancies undergoing UCBT at a single institution. CD8þ cell
content was critical for success.
METHODS
Patient eligibility, graft selection, conditioning regimens, immune sup-
pression, and supportive care have been previously reported [7,8] and are
summarized below.
Patients
All patients with hematological malignancies undergoing myeloablative
single-unit UCBT (sUCBT) at our institution between May 1997 and January
2012 were included in the study.
Patients with hematological malignancies were eligible for enrolment if
they met the following criteria: (1) allogeneic hematopoietic cell trans-
plantation was considered the best therapeutic option, (2) a suitable related
donor (HLA identical or 1 antigen mismatched) was not available, (3) there
was a lack of a suitable HLA-matched unrelated donor at a reasonable timeTransplantation.
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was a suitable UCB unit available, as described below.
Patients receiving ex vivo expanded grafts were excluded. The institu-
tional review board approved the protocol and written informed consent
was obtained from all patients, according to the Declaration of Helsinki.
Cord Blood Unit Selection
The search of UCB units was conducted by the Spanish Registry of
Bone Marrow Donors (Registro Español de Donantes de Médula Ósea). A
degree of HLA matching between the UCB unit and the recipient greater
or equal to 4 of 6 (considering HLA-A and -B at antigen level and -DRB1 at
allele level) was required. Those units fulﬁlling HLA-matching criteria
were ranked according to their content of TNCs and CD34þ cells. The
minimum number of TNCs and CD34þ cells required for selection of UCB
units changed over time. Until 2005, only a TNC dose 1.5  107/kg
recipient’s body weight was required (71 patients, 36%). During this early
period, CD34þ cell content was also closely monitored, but a threshold for
UCB unit selection was not established. In 2006 and 2007, the numbers of
TNCs and CD34þ cells required were 2  107/kg and 1  105/kg
recipient’s body weight (47 patients, 24%), respectively. Since 2008, the
minimum cell dose requirements are TNCs >150  107 and CD34þ cells
>70  105, without taking into account recipient’s body weight (82
patients, 41%). Cell dose was always considered the most important
criteria for UCB unit selection.
Conditioning Regimen, Graft-versus-Host Disease Prophylaxis and
Treatment, and Supportive Care
Two myeloablative conditioning regimens were used and have been
described in detail elsewhere [7,8]. Brieﬂy, the ﬁrst 71 patients received
thiotepa (10 mg/kg), busulfan (12 mg/kg orally or 9.6 mg/kg i.v.), and
cyclophosphamide (120 mg/kg), whereas the last 129 patients received the
same preparative regimen but cyclophosphamide was replaced by ﬂudar-
abine (150 mg/m2). All patients received antithymocyte globulin (ATG);
horse ATG (Lymphoglobuline, Merieux, Lyon, France; total dose, 60 mg/kg)
in the ﬁrst 32 patients (16%) and rabbit ATG (Thymoglobulin, Sangstat/
Genzyme, Lyon, France; total dose, 6 to 8 mg/kg) in the last 168 patients
(84%).
All patients received cyclosporine 1.5 mg/kg/12 hours i.v., followed by 3
to 5 mg/kg/12 hours orally, when oral intake was possible, with slow
tapering starting between day þ90 and þ180 and with discontinuation on
day þ180 or before if feasible. Cyclosporine was combined with prednisone
in 150 patients (.5 mg/kg from dayþ7 toþ14, 1 mg/kg from dayþ14 toþ28,
and then slowly tapered in 120 cases, and 1 mg/kg from day þ14 to þ28 in
30 patients) or withmycophenolatemofetil (MMF) (15mg/kg/12 hours until
day þ28) in the remaining 50 patients. Patients developing acute graft-
versus-host disease (GVHD) received high-dose methylprednisolone as
initial therapy (2 to 20 mg/kg/day) and ATG was used in refractory cases [7].
Chronic GVHD was treated with prednisone (1 mg/kg/day).
Patients were kept in reverse isolation under high-efﬁciency particulate
air ﬁltration. Ciproﬂoxacin and cotrimoxazole were given as antibacterial
prophylaxis. For antifungal prophylaxis, ﬂuconazole, itraconazole, and vor-
iconazole were sequentially used during the study period. The use of
intravenous antibiotics and antifungal agents and the transfusion policy
were those usually employed when handling neutropenic patients. All
transfused products were irradiated and depleted of leukocytes. As cyto-
megalovirus (CMV) prophylaxis, all patients received intravenous acyclovir
(400 mg/m2 every 12 hours) from day -5 until engraftment, followed by
intravenous ganciclovir (5 mg/kg per day 3 to 5 days per week) or oral
valganciclovir (900 mg per day) from engraftment until day 100 after
transplantation. CMV infection surveillance and treatment have been
described in detail elsewhere [8]. Nonspeciﬁc intravenous immunoglobulins
(500 mg/kg) were administered weekly until day þ100 and monthly
thereafter during the ﬁrst year after the transplantation.
Cellular Assays
UCB units were thawed and washed using the standard method of
Rubinstein et al., slightly modiﬁed [7]. Samples for cell counts, including
TNCs, CD34þ, CD3þ, CD4þ, CD8þ, CD16þ, CD56þ, and CD19þ cells, were
drawn directly from the UCB unit bag(s) after thawing and washing and
before infusion.
The CD34þ cell contentwas quantiﬁed by ﬂowcytometrywith CD34 and
CD45 monoclonal antibodies conjugated to phycoerythrin and ﬂuorescein,
respectively (Becton Dickinson, San Jose, CA). The lymphoid population was
analyzed using CD19 and CD3 monoclonal antibodies for total B and T
lymphocytes, respectively. T lymphocytes subpopulations were analyzed
using CD8, CD4, CD16, and CD56 monoclonal antibodies (Becton Dickinson).
Flow cytometry analysis was performed on the FACSCalibur and FACScanto
cytometer (Becton Dickinson). Acquisition and analysis of events were doneby using Cellquest and FACSDiva software, respectively (Becton Dickinson).
A double platform system was used for cell assays. The automated cell
counter used was Sysmex K21 (Roche, Basilea, Switzerland).
Deﬁnitions
Neutrophil engraftment was deﬁned as an absolute neutrophil count
equal or greater than .5  109/L on 3 consecutive days. Platelet engraftment
was deﬁned as a platelet count equal or greater than 20  109/L without
transfusional support for 7 consecutive days. Patients who died 28 days after
transplantation without neutrophil engraftment were considered graft
failures. Time to neutrophil or platelet engraftment was deﬁned as the
time required to reach the ﬁrst day of engraftment. Acute and chronic graft-
versus-host disease (GVHD) were deﬁned and graded according to standard
criteria [9-11]. Disease status at the time of transplantation was classiﬁed as
follows: (1) early stage: acute leukemia, myelodysplastic syndrome, and
lymphoma in the ﬁrst complete remission untreated myelodysplastic syn-
drome with <5% blasts and/or chronic myelogenous leukemia (CML) in the
ﬁrst chronic phase; (2) intermediate stage: acute leukemia, lymphoma, or
myelodysplastic syndrome in a second or further compete remission and
CML in a second or further chronic or accelerated phase; and (3) advanced
stage: acute leukemia and lymphoma not in remission, CML in blast crisis,
and untreated refractory anemia with excess blasts. Nonrelapse mortality
(NRM) was deﬁned as death from any cause without evidence of relapse.
Disease-free survival (DFS) was deﬁned as survival from the time of trans-
plantation without evidence of disease relapse. Overall survival (OS) was
deﬁned as survival from the time of transplantation.
Prognostic Factors
Variables considered for prognostic factor analysis were age, gender,
recipient weight, recipient CMV serology, diagnosis, disease status at
transplantation, HLA match, ABO blood group compatibility, conditioning
regimen, GVHD prophylaxis, and TNCs, CD34þ, CD3þ, CD4þ, CD8þ, CD16þ/
CD56þ, and CD19þ cells infused. Continuous variables were introduced as
such in multivariable regression procedures but were dichotomized at their
most discriminative cut-off point for depicting their effect on univariable
analyses.
Statistical Analysis
Correlation between variables was analyzed by Spearman’s correlation
test. The variable inﬂation factor was estimated to quantify the severity of
possible colinearity between the different cell subsets. Probabilities of
engraftment, NRM, and GVHD, and relapse were estimated by the cumula-
tive incidence method [12]. Unadjusted time-to-event analyses were per-
formed using the Kaplan-Meier estimate, and, for comparisons, the log-rank
test was used [13]. Cox proportional hazard regression method and Fine and
Graymethod for competing events were used for multivariable analysis [14].
For the Cox models, the proportional hazards assumption was tested and
conﬁrmed to be satisﬁed, by correlating scaled Schoenfeld residuals with a
transformation of time. Characteristics selected for inclusion in the multi-
variable model were those with some indication of association in uni-
variable analysis (P < .10). Only cases with complete data (n ¼ 189) were
considered in multivariable modeling. The forward stepwise procedure was
stopped when the P value for entering an additional variable was above .05.
The follow-up of the patients was updated on April 1, 2013 and all follow-up
data were censored at that point. Two-sided P values <.05 were considered
statistically signiﬁcant and no adjustment for multiple testing was applied.
Statistical analysis were conducted using R version 2.12.2 (The CRAN proj-
ect) with packages car v2.0-16, rms v3.6-3, prodlim v1.3.3, cmprsk v2.2-4,
survival v2.37-4 and fmsb v0.4.1.
RESULTS
Patient, Graft, and Transplantation Characteristics
Data from 200 transplantations fulﬁlling the inclusion
criteria were analyzed. Patient, graft, and transplantation
characteristics are shown in Table 1. Brieﬂy, median age was
32 years (range, 15 to 55), 145 patients (73%) had acute leu-
kemia, 60 (30%) underwent transplantation while in an
advanced phase, and 139 (70%) received UCB units mis-
matched at 2 HLA loci.
Cell Content of the Umbilical Cord Blood Units
Table 2 summarizes the dose of the different cell pop-
ulations present in the grafts. The R correlation coefﬁcient
between TNCs infused and CD34þ, CD3þ, CD8þ, and CD4þ
cells infusedwas .66, .66, .53, and .65, respectively (P< .01 for
Table 1
Patient and Transplantation Characteristics
Characteristics Value
Age, median (range), yr 32 (15-55)
Patient’s gender
Male 127 (63.5)
Female 73 (36.5)
Diagnosis
Acute myeloid leukemia 73 (36.5)
Acute lymphoblastic leukemia 72 (36)
Myelodysplastic syndrome 10 (5)
Chronic myeloid leukemia 26 (13)
Chronic lymphoproliferative disorder 14 (7)
Other 5 (2.5)
Disease status*
Early 88 (44)
Intermediate 52 (26)
Advanced 60 (30)
Recipient’s body weight, median (range), kg 72 (37-112)
CMV serologic status
Positive 157 (78.5)
Negative 43 (21.5)
Previous autologous HCT
Yes 23 (11.5)
No 177 (88.5)
Conditioning regimen
TT þ BU þ CY 71 (35.5)
TT þ BU þ FLU 129 (64.5)
Type of ATG
Equine 32 (16)
Rabbit 168 (84)
GVHD prophylaxis
CSA þ MMF 50 (25)
CSA þ PRED 150 (75)
Donor-receptor gender disparity
Male-male 64 (32)
Male-female 35 (18)
Female-female 37 (19)
Female-male 63 (32)
ABO group incompatibility
No 93 (46.5)
Major incompatibility 51 (25.5)
Minor incompatibility 56 (28)
HLA matchy
6 out of 6 11 (5)
5 out of 6 50 (25)
4 out of 6 139 (70)
HCT indicates hematopoietic cell transplantation; TT, thiotepa; BU,
busulfan; CY, cyclophosphamide; FLU, ﬂudarabine; CSA, cyclosporine;
PRED, prednisone.
Data presented are n (%), unless otherwise indicated.
* Deﬁnitions of early, intermediate, and advance stage disease status at
the time of transplantation are shown in Supplemental Material.
y By considering HLA-A and -B at antigen level and -DRB1 at allele level.
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CD8þ, and CD4þ cells infused was .48, .41, and .47, respec-
tively (P < .01 for all comparisons). However, according toTable 2
Cell Content of the Cord Blood Units
Cell Type Median (Range)
At time of freezing
TNCs  107 per kg 2.9 (1.4-7.5)
CD34þ cells  105 per kg 1.6 (.2-6.8)
At time of infusion
TNCs  107 per kg 2.4 (1-5.9)
CD34þ cells  105 per kg 1.3 (.1-10.1)
Lymphocytes  106 per kg 9.9 (2.8-32.7)
CD3þ cells  106 per kg 5.6 (1.5-17.4)
CD4þ cells  106 per kg 4.1 (.1-12.1)
CD8þ cells  106 per kg 1.6 (.5-10.2)
CD19þ cells  106 per kg 1.9 (.2-10.9)
CD16þ cells  106 per kg 2.1 (.4-9.2)variable inﬂation factor results, there was no statistically
signiﬁcant colinearity between TNCs, CD34þ cells, and CD8þ
cells.
Predictive Factors of Outcome
A summary of the results of multivariable analyses for the
different transplantation outcomes is offered in Table 3. The
data of univariable analyses are presented as web extra
material (Supplementary material).
Neutrophil engraftment
Eight patients (4%) died before day 28 after trans-
plantation (median time, 16 days; range, 9 to 24) and were
considered not evaluable for engraftment. Nine of 192 pa-
tients (5%) had graft failure and the remaining 183 patients
(95%) achieved neutrophil engraftment at a median of
21 days (range, 11 to 57). The cumulative incidence of
neutrophil engraftment at day 60 after transplantation was
92% (Figure 1A). Multivariable analysis showed that higher
CD34þ (P < .001) and CD8þ (P ¼ .001) cell dose, diagnosis of
acute leukemia (P ¼ .01), and negative CMV serological
status of the recipient (P ¼ .01) were independently asso-
ciated with improved cumulative incidence of engraft-
ment. Figure 1B to 1D depict the relationship between
CD8þ and CD34þ cell doses and neutrophil engraftment.
The median number of infused CD8þ cells in patients
without evidence of engraftment was 1.2  106/kg (range,
.5 to 3.3).
Platelet engraftment
Platelet recovery was achieved in 135 patients at a
median time of 51 days after UCBT (range, 23 to 188). The
cumulative incidence of platelet engraftment was 67%
(Figure 2A). Multivariable analysis showed that a higher
CD8þ cell dose at infusion (P ¼ .008) and use of ﬂudarabine
rather than cyclophosphamide in the conditioning
regimen (P ¼ .03) were independently associated with
improved cumulative incidence of platelet recovery. The
effect of CD8þ cell dose on platelet recovery is shown in
Figure 2B.
Acute and chronic GVHD
The cumulative incidence of acute GVHD grade II to IV and
grade III to IV at 100 days was 43% and 25%, respectively. The
cumulative incidence at 4 years of chronic and chronic
extensive GVHD was 61% and 41%, respectively. In multivar-
iable analysis, the incidence of acute grade II to IV GVHD was
lower in patients diagnosed of acute leukemia (P ¼ .004) and
in those receiving rabbit ATG (P ¼ .0003), whereas the inci-
dence of chronic GVHDwas lower in patients receivingmajor
ABO incompatible grafts (P ¼ .008) and in those receiving a
higher CD19þ cell dose (P ¼ .007).
Relapse risk
Fifty-one patients relapsed after UCBT, with a cumulative
incidence of relapse at 4 years of 24%. The 4-year cumulative
incidence of relapse risk was higher in patients diagnosed of
acute leukemia (P ¼ .0006) and in patients who underwent
transplantation in advanced phase (P ¼ .004).
NRM
After a median follow-up of 79 months (range, 17 to 180),
144 patients (72%) have died, 96 (48%) without relapsing and
48 (24%) after relapse. The 4-year NRM was 46% (95% con-
ﬁdence interval [CI], 39% to 53%). Multivariable analysis
Table 3
Factors Affecting the Outcome after UCBT in Multivariable Analysis
Favorable Variables for Outcomes HR (95% CI) P Value
Myeloid engraftment
Diagnosis of acute leukemia 1.53 (1.09-2.14) .01
CMV status negative 1.57 (1.1-2.24) .01
CD34þ cells infused 1.19 (1.07-1.32) .001
CD8þ cells infused 3.5 (1.72-7.15) <.001
Platelet engraftment
CD8þ cells infused 3.25 (1.36-7.79) .008
Use of ﬂudarabine 1.5 (1.03-2.16) .03
Nonrelapse mortality
CD8þ cells infused .1 (.02-.7) .02
Diagnosis of acute leukemia .52 (.35-.78) .002
Relapse risk
Diagnosis of acute leukemia 13 (3-56.27) <.001
Early disease stage 2.46 (1.34-4.52) .004
Disease-free survival
CD8þ cells infused 1.8 (1.2-2.7) .006
Nonadvanced disease status* 2.1 (1.5-3) <.001
Overall survival
CD8þ cells infused 1.7 (1.1-2.5) .01
Nonadvanced disease status 2.1 (1.5-3) <.001
HR indicates hazard ratio.
* Nonadvanced disease status includes early and intermediate disease
status at transplantation (see deﬁnitions in Supplemental Material).
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of acute leukemia (P ¼ .002) were associated with a lower
NRM. The impact of CD8þ cell dose on NRM is drawn on
Figure 3A.
DFS and OS
The 4-year DFS and OS of the entire cohort were 29% (95%
CI, 22% to 35%) and 31% (95% CI, 25% to 38%), respectively.
Variables associated with improved DFS and OS in multi-
variable analysis were a higher CD8þ cell dose (P ¼ .006 for
DFS and P ¼ .01 for OS) and nonadvanced disease status
(P < .001 for DFS and P < .001 for OS). The effect of CD8þ cell
dose on DFS and OS is depicted in Figure 3B and 3C,
respectively.
The dose of cryopreserved TNCs and CD34þ cells did not
show any signiﬁcant relationship with GVHD, NRM, relapse
risk, DFS, or OS. The cryopreserved CD34þ cells only inﬂu-
enced myeloid recovery in univariable analysis.
DISCUSSION
This study shows that the number of CD8þ cells of the
graft is a major and independent determinant of neutrophil
and platelet engraftment, NRM, DFS, and OS after myeloa-
blative sUCBT in adult patients with hematological malig-
nancies. This novel ﬁnding is clinically relevant because the
inclusion of CD8þ cell content among the factors used for
UCB unit selection could improve the results of UCB
transplantations.
Cell dose and HLAmatch are universally recognized as the
most relevant criteria for UCB unit choice and outcome after
UCBT [2]. TNC content remains the preferred measurement
of cell dose and is used by most transplantation centers for
UCB selection, with 2.5  107 TNCs per recipient’s body
weight usually recommended as the critical threshold that
should be fulﬁlled [15]. Nevertheless, as occurred in most
studies in adults, TNCs were not associated with any partic-
ular outcome. It is likely this ﬁnding reﬂects our current
inability to offer a sufﬁciently high number of cells to adult
recipients to improve results after a minimum threshold of
TNCs has been transplanted. This is in contrast with data inchildren, in whom several large registry series have shown
that an additional cut-off point of 5  107 TNCs per kg could
be beneﬁcial [16,17].
Our data reinforce the importance of CD34þ cell dose on
engraftment after UCBT [18,19] and the need to include this
characteristic as amajor criterion for UCB unit selection [2,3].
Interestingly, the amount of CD34þ cells appeared to affect
the speed of myeloid recovery rather than the overall
engraftment rate. It should be taken into account that these
ﬁndings may be applicable only when, as in our center, a
minimum number of CD34þ cells has been used for UCB
selection (see Supplemental Material). In contrast to 1 series
[18] but in accordance with several studies [6], the CD34þ
cell dose was not independently associated with other short-
or long-term transplantation outcomes. In sharp contrast,
CD8þ cell dose emerged as an important factor for most
relevant transplantation outcomes. First, the number of
CD8þ cells inﬂuenced not only the speed of neutrophil re-
covery but also the overall neutrophil engraftment rate.
Further, in contrast to the TNC or CD34þ cell dose, CD8þ cell
content also predicted time to platelet recovery. To our
knowledge, only 1 previous report has suggested a role of
CD8þ cells on neutrophil engraftment after UCBT [20].
However, in that study, this relevance was restricted to pa-
tients receiving a low dose of CD34þ cells. The mechanisms
by which donor T cells could inhibit the host ability to reject
an allograft remain largely undeﬁned. However, the presence
of a graft-versus-host immunological response mediated by
CD8þ cells from the graft has been suggested in the double-
unit UCBT platform, where unit dominance is strongly
related to the number of CD8þ cells present in each UCB unit
[21,22]. In addition, CD8þ cells have also been shown to
facilitate engraftment in murine models [23,24].
The most important ﬁnding of this study was that the
CD8þ cell dose also had an independent impact on NRM, DFS,
and OS. To our knowledge, this observation has never been
reported. The only characteristics related to the graft that
have previously shown to affect OS in adult recipients have
been the TNCs dose after sUCBT [25] and the CD34þ cell dose
after double-unit UCBT [18]. Although the basic mechanisms
underlying CD8þ cell content effect are unknown, several
hypotheses could explain its relevance. Obviously, a greater
CD8þ cell dose could have offered a beneﬁt in early NRM by
improving the engraftment rate but, noteworthy, a beneﬁt
close to 10% on NRM and OS was also observed for patients
surviving beyond 100 days after the transplantation.
Whether this long-term advantage is due to improved im-
mune recovery or other causes is, at present, unknown.
Further, the subpopulations of CD8þ cells of the UCB unit
potentially responsible for the relevance of CD8þ cells on
engraftment and NRMmerit close consideration because the
CD8þ cell content of the UCB unit could likely be a surrogate
for 1 or some of them. Both the large naïve (CD45RAþCCR7þ)
and the small alloreactive effector-memory (CD45RA and
CD45RAþCCR7) CD8þ T cell subpopulations present in UCB,
the latter with potential capacity to recognize maternal an-
tigens, including HLA noninherited antigens as well as
different pathogens, could be involved both in engraftment
facilitation and immune response to viral infections occur-
ring after the transplantation. The potential role of the latter
lymphocyte subset is favored by the close agreement be-
tween our results with data showing the positive impact of
noninherited antigens match on engraftment and NRM after
UCBT [26]. Furthermore, it has been shown that a CMV-
speciﬁc T cell response derived from the UCB graft is
Figure 1. Unadjusted cumulative incidence of myeloid engraftment in the overall series (A), and according to CD8þ cells infused  106/kg (B), CD34þ cells
infused  105/kg (C), and both cell populations (D). For patients who received UCB units above and below 1.6  106 CD8þ cells/kg, the cumulative incidence of myeloid
engraftment at 60 days and the median time to neutrophil recovery were 96% and 19 days and 87%, and 22 days, respectively (P ¼ .007) (B). For patients who received
UCB units above and below 1.3  105 CD34þ cells/kg, those ﬁgures were 92% and 18 days and 91% and 23 days, respectively (P ¼ .005) (C). The numbers of CD34þ and
CD8þ cells were able to deﬁne 4 groups regarding the speed and overall rate of myeloid engraftment (D), with group 1 being those grafts with high doses of both
CD34þ cells (>1.3  105 per kg) and CD8þ cells (>1.6  106 per kg), group 2 those with high dose of CD34þ cells (>1.3  105 per kg) but low dose of CD8þ cells
(<1.6  106 per kg), group 3 those with low dose of CD34þ cells (<1.3  105 per kg) but high dose of CD8þ cells (>1.6  106 per kg), and group 4 those with low doses
of both CD34þ cells (<1.3  105 per kg) and CD8þ cells (<1.6  106 per kg). The cumulative incidence of and median time to myeloid engraftment were 95% and
17 days for group 1 (high rate and fast engraftment), 88% and 19 days for group 2 (low rate but fast engraftment), 97% and 23 days for group 3 (high rate but slow
engraftment), and 87% and 23 days for group 4 (low rate and slow engraftment), respectively (P ¼ .009).
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These UCB-derived T cells are able to rapidly proliferate
in vitro but fail to achieve sufﬁcient numbers in vivo to
control CMV reactivation, suggesting that the total amount of
this alloreactive T cells in the UCB unit could be clinically
relevant to augment immunity against pathogens [27].
Currently, we are analyzing in depth the potential impact of
CD8þ cell dose on the incidence of speciﬁc bacterial, viral,
and fungal infections and on immune reconstitution after
UCBT, and we are also studying the speciﬁc CD8þ T cell
fractions that could account for our ﬁndings. It should be
taken into account that these results were observed with the
use of ATG in the conditioning regimen and might not be
applicable in other settings. The lack of inﬂuence of TNCs and
CD34þ cells, whether cryopreserved or infused, on NRM, DFS,and OS strongly argues against the hypothesis that the
relevance of CD8þ cell dose is merely a surrogate for graft
size, reﬂecting the fact that this cell subtype is better pre-
served during cryopreservation, storage, and thawing than
other cell subsets of the graft.
One caveat of this large single-center study is that it
included a heterogeneous patient population and encom-
passed a long period of time. However, patients received a
relatively homogeneous conditioning regimen and support-
ive care and the criteria used for UCB unit selection were
quite uniform. Further, CD8þ cell dose was never used for
UCB unit choice, which excludes a potential selection bias in
the results. It should be also noted that cell populations were
analyzed in samples drawn from the UCB bag infused to the
recipient, using the same method, reagents, and equipment
Figure 2. Unadjusted cumulative incidence of platelet engraftment in the overall series (A) and according to CD8þ cells infused  106 per kg (B). For patients who
received UCB units with > 1.6  106 CD8þ cells/kg, the cumulative incidence of platelet engraftment at 180 days and median time to platelet engraftment were 77%
and 44 days, respectively, whereas for those receiving a lower CD8þ cell dose they were 57% and 62 days, respectively (P ¼ .0001).
F. Moscardó et al. / Biol Blood Marrow Transplant 20 (2014) 1744e1750 1749throughout the study, and in a single laboratory, overcoming
1 of the most important limitations of registry-based studies.
In fact, the cell composition of UCB units in our series was not
different than in previous reports in terms of TNCs, CD34þ
cells [4,5,28], and lymphocyte subsets [20]. As expected, the
number of T cells in UCB was 10 to 100 times lower than in
bone marrow or mobilized peripheral blood [29], but it was
higher than in T celledepleted grafts, a strategy resulting in aFigure 3. Unadjusted cumulative incidence of NRM (A), DFS (B), and OS (C) accord
100 days, 1 year, and 4 years was 13%, 34%, and 39% for patients with CD8þ cells above
that level (P ¼ .03). DFS and OS for patients with CD8þ cells above 2.2  106 CD8þ cells
who received a lower CD8þ cell dose (P ¼ .02 and P ¼ .04, respectively).high rate of graft failure [30]. Interestingly, no signiﬁcant
colinearity was observed between CD8þ cells and TNCs or
CD34þ cells, likely because of the high variability in T cell
composition present in UCB grafts, which merits further
study.
If the relevance of CD8þ cell number is conﬁrmed by
others, this characteristic should be considered an additional
criterion for UCB unit selection that would need to be offereding to CD8þ cells infused  106 per kg. The cumulative incidence of NRM at
1.6  106 CD8þ cells per kg whereas it was 26%, 46%, and 54% for those below
per kg were 38% and 42%, respectively compared with 23% and 26% for patients
F. Moscardó et al. / Biol Blood Marrow Transplant 20 (2014) 1744e17501750to transplantation centers. In this sense, quantiﬁcation of
CD8þ cells is standardized, routinely used, and would not
represent a technical or economic burden to UCB banks.
In conclusion, this study demonstrates that outcome after
UCBT in adults with hematological malignancies was better
when UCB grafts had a greater CD8þ cell content. Taking into
account CD8þ cell dose for graft selection could have sig-
niﬁcant clinical implications in the UCB transplantation
setting, where measures focused on improving engraftment,
reducing NRM, and increasing long-term survival are
desperately needed.ACKNOWLEDGMENTS
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